ArticleMultiple sclerosis journal - experimental, translational and clinical
Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Biopsy-proven tumefactive demyelinating lesions: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Article
- Primary central nervous system lymphoma and tumefactive demyelinating lesions in multiple sclerosis: a retrospective observational cohort study.Frontiers in oncology · 2026Article
- Unusual Stroke-Like Presentation of Tumefactive Multiple Sclerosis in a 27-Year-Old Man.Cureus · 2025Article
- Tumefactive demyelinating lesions: A literature review of recent findings.Neurosciences (Riyadh, Saudi Arabia) · 2024Review
- Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.Scientific reports · 2024Article
- High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study.BMC neurology · 2023Article
- Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients.Annals of clinical and translational neurology · 2023Article
- Spinal cord and brain corticospinal tract lesions are associated with motor progression in tumefactive multiple sclerosis.Multiple sclerosis and related disorders · 2023Article
- Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.Frontiers in neurology · 2023Article
- Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.European journal of neurology · 2022Article
- Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.Therapeutic advances in neurological disorders · 2021Article
- Deep Learning With Data Enhancement for the Differentiation of Solitary and Multiple Cerebral Glioblastoma, Lymphoma, and Tumefactive Demyelinating Lesion.Frontiers in oncology · 2021Article
- Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.Frontiers in neurology · 2020Article
- Tumefactive demyelination in older adults: A scoping review of published cases.Multiple sclerosis journal - experimental, translational and clinicalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLarge demyelinating lesions with possible mass effect (tumefactive multiple sclerosis or tumefactive demyelination) can be mistaken for tumour-like space-occupying lesions suggesting a malignant outcome.
methodsWe reviewed our own experience of multiple sclerosis subjects (
resultsNo patient increased in extended disability status scale (EDSS). Overall, lesion regression was associated with improved EDSS. Lesion regression was also associated with therapy versus no therapy. No specific therapy or corticosteroid infusions improved EDSS over the long term. The absence of enhancement on follow up on magnetic resonance imaging portended lesion regression.
conclusionTumefactive demyelination may predict a more benign overall course and is susceptible to traditional immunomodulatory treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.